LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically-proven NSCLC.
• Age ≥ 18 years.
• Advanced or metastatic stage IV.
• Treatment-naïve patient.
• Eligibility to first-line treatment with immune checkpoint inhibitor.
• Measurable disease according to RECIST 1.1 criteria on CT-Scan.
• Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.
• No ALK or EGFR gene alteration.
• Availability of tumor tissue for NGS analysis (7 slides).
⁃ PS 0 or 1.
⁃ Signed informed consent of the patient.
Locations
Other Locations
France
Hopital Ambroise Pare
RECRUITING
Boulogne-billancourt
Institut Curie
RECRUITING
Paris
Institut Curie
RECRUITING
Saint-cloud
Contact Information
Primary
Marie-Emmanuelle Legrier
marieemmanuelle.legrier@curie.fr
01 56 24 56 49
Time Frame
Start Date: 2021-05-22
Estimated Completion Date: 2030-06-03
Participants
Target number of participants: 300
Treatments
Experimental: NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.
Patient with histologically proven Non Small Cell Lung Cancer in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.~Presence of a mutation after NGS analysis is required for ctDNA follow-up.
Related Therapeutic Areas
Sponsors
Leads: Institut Curie